296 related articles for article (PubMed ID: 21501328)
41. Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder.
Marencak J; Cossons NH; Darekar A; Mills IW
Neurourol Urodyn; 2011 Jan; 30(1):75-82. PubMed ID: 20886571
[TBL] [Abstract][Full Text] [Related]
42. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
43. The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
Oresković S; But I; Banović M; Goldstajn MS
Coll Antropol; 2012 Mar; 36(1):243-8. PubMed ID: 22816227
[TBL] [Abstract][Full Text] [Related]
44. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Abrams P; Kaplan S; De Koning Gans HJ; Millard R
J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
[TBL] [Abstract][Full Text] [Related]
45. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Chapple C
Urologe A; 2007 Apr; 46(4):422, 424-6; author reply 426, 428. PubMed ID: 17384923
[No Abstract] [Full Text] [Related]
46. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
[TBL] [Abstract][Full Text] [Related]
47. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618
[TBL] [Abstract][Full Text] [Related]
48. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder.
Tanaka Y; Masumori N; Tsukamoto T
Int J Urol; 2010 Sep; 17(9):796-800. PubMed ID: 20649825
[TBL] [Abstract][Full Text] [Related]
49. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
[TBL] [Abstract][Full Text] [Related]
50. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.
Chung DE; Te AE; Staskin DR; Kaplan SA
Urology; 2010 May; 75(5):1144-8. PubMed ID: 20206978
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
[TBL] [Abstract][Full Text] [Related]
53. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
[TBL] [Abstract][Full Text] [Related]
54. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
[TBL] [Abstract][Full Text] [Related]
55. Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without voiding dysfunction.
Wu WY; Hsiao SM; Chang TC; Lin HH
J Obstet Gynaecol Res; 2011 May; 37(5):436-41. PubMed ID: 21272154
[TBL] [Abstract][Full Text] [Related]
56. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
Staskin DR; Te AE
BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
[TBL] [Abstract][Full Text] [Related]
57. Solifenacin succinate for the treatment of symptoms of overactive bladder.
Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
[TBL] [Abstract][Full Text] [Related]
60. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
